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INTRODUCTION 
Thalassaemia major is a genetic disease characterized by 
a reduced ability to produce hemoglobin.
1 
Beta-
Thalassemia, originally named Cooley anemia, is an 
inherited blood disease that are created by effective 
mutations in the hemoglobin synthesis.
2
 Various types of 
thalassemia are inherited anemia caused by mutations at 
the globin gene loci on chromosomes 16 and 11, affecting 
the production of alpha or beta-globin protein, 
respectively.
2 
This is the most common hereditary anemia 
in the world and prevalent in Africa, Mediterranean 
countries and Asia.
1-3 
In Iran in average4.5% of 
population is beta-thalassemia carriers and its incidence 
rate indifferent provincesvariesbetween1-10%.
4,5
 
Thalassemiaisone of the world's most extensive genetic 
diseases that affect about 5% of world population. Beta-
thalassemia is divided into three main groups: 
thalassemia major, thalassemia intermediate and minor.
5-7
 
Long duration transfusion of blood is the best treatment 
for major thalassemia patients.
8
 Despite the problems of 
anemia improved after the presentation of regimes hyper 
transfusion, hemosiderosis of the thalassemia disease and 
its treatment is one of the most limiting factors in these 
patients. Injecting too much blood can lead to the 
accumulation of iron in the body and non-excretion of 
excess iron leads to serious complications.
9,10 
Symptoms 
of iron overload in these patients occur as deposition in 
the heart and endocrine glands in the form of diabetes 
mellitus, hypothyroidism, hypoparathyroidism, growth 
retardation, hypogonadism, and finally liver fibrosis and 
cirrhosis.
11,12
 
Iron overload complications in different organs, is one of 
the main problems in patients with thalassemia major 
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treated with repeated transfusions. Therefore new 
therapies are sought to decrease these complications, but 
an appropriate treatment strategy is not defined yet. Iron 
chelating therapy begins when the patient has received 
10-20 blood transfusions or serum ferritin level has 
reached >1000 ng/ml. 
Subcutaneous Deferoxamine as chelating agent is often 
not tolerated by patients and rejecting its application 
causes iron overload followed by complications. So, 
alternative methods to achieve better toleration and lower 
Deferoxamine doses are desirable. 
It was shown that early treatment of major thalassemia 
patients with Deferoxamine can improve prognosis and 
quality of life of patients and reduce the incidence of 
major complications due to iron overload (e.g., heart 
failure). The benefits of long-term treatment with 
Deferoxamine in increasing survival and reducing cardiac 
complications in patients with transfusion-dependent beta 
thalassemia have been documented well.
13
 
Deferoxamine is currently recognized as a golden 
standard in treatment of iron. Until now many treatment 
regimens using Deferoxamine are introduced but results 
are still controversial and from all suggested methods the 
concomitant use of intravenous Deferoxamine and blood 
seem to be the best.
14 
There are many evidences for 
importance of concomitant use of intravenous 
Deferoxamine in decreasing morbidity and mortality of 
the affected patients.
13 
In this study we used this regimen 
which is not used routinely in thalassemia clinics. The 
present study aimed to investigate the effect of 
concomitant administration of intravenous Deferoxamine 
with blood transfusion on serum ferritin level in 
thalassemia major patients.  
METHODS 
In this retrospective cross-sectional study, records of 34 
patients with beta-thalassemia major at Bu-Ali hospital in 
Ardabil city, who were referred to receive regular blood 
transfusions in April 2013 to April 2014, were studied. 15 
(45.7%) of the patients were males. The mean age of 
patients was 20.1±5.7 (range 8-28) years. All the patients 
were over 8 years old and transfusion-dependent using 
Deferoxamine as iron-chelating agent, some with poor 
compliance. The diagnosis had been made according to 
hemoglobin electrophoresis results and complete blood 
count. The study protocol was approved by the Ethics 
Committee of Ardabil University of Medical Sciences 
(code ARUMS1013). Informed written consent was 
obtained from all parents. The inclusion criteria included 
the absence of abnormalities in organs and exclusion 
criteria included provencirrhosis or having complications 
due to Deferoxamine such as swelling of the skin - skin 
rash - a rash and anaphylactic reactions. 
The mean amount of ferritin and subcutaneous 
Deferoxamin before start of intervention was checked 
and considered as the baseline in beta-thalassemia major 
patients who had been treated with monthly routine blood 
transfusions. All patients received intravenous 
Deferoxamine concomitant with monthly blood 
transfusion for six months. After six months the mean 
values of ferritin, subcutaneous Deferoxamine were 
compared with baseline. 
Deferoxamine was used as 500 mg per 5 kg of body 
weight infusion during 8 hours. In patients <10 years old 
50 mg and over 10 years old 100 mg Vitamin C was 
administered.  
Necessary information including demographic data, 
hemoglobin levels, rate of Deferoxamine and its side 
effects and history of splenectomy collected for all 
patients by checklist in follow up period. 
The normality of data was checked by K-S test in 
SPSS.18. The results were expressed as mean±SD. We 
used t-test and paired t-test to compare the mean values 
between the two groups with baseline three and six 
months after intervention. The P<0.05 was considered as 
significant for all test results. 
RESULTS  
The mean value of ferritin in baseline was 3156.3±403.6 
µg/dl which significantly decreased to 2790.2±367.8 
three months after study begin (P=0.04). But the 
difference between ferritin six months after it compared 
with baseline was not statistically significant (Figure 1). 
 
Figure 1: The amount of ferritin in baseline, three and 
six months after study begin. 
The mean value of subcutaneous Deferoxamine three 
months after intervention was 34.4±5.8 and in baseline it 
was 75.4±12.9, The rate of reduction was statistically 
significant (P=0.002). 
The mean value of subcutaneous Deferoxamine six 
months after intervention was 21±5 and in baseline it was 
75.4±12.9. The rate of reduction was statistically 
significant (P=0.001). 
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The reductionin rate of subcutaneous Deferoxamine three 
and six months after study begins compared with baseline 
were 54.4% and 73.2%; respectively. In this study, the 
mean value of Deferoxamine in three months after study 
begins was 32.4±9.2 and in baseline it was 85.9±17.4 
(Figure 2). There was a significant reduction in the rate of 
Deferoxamine compared to baseline (P=0.001). 
 
Figure 2: the mean value of used subcutaneous 
Deferoxamine amount in baseline three and six 
months after study begin. 
In evaluation the effect of Splenectomy on subcutaneous 
Deferoxamine in three and six months after study begin, 
results showed that there was a significant reduction in 
the rate of subcutaneous Deferoxamine in patients who 
were Splenectomized (P=0.025, P=0.033). 
Also, in patients with no splenectomy there was a 
significant reduction in subcutaneous Deferoxamine three 
and six months after intervention compared with baseline 
(P=0.002, P=0.024). 
In patients with Splenectomy, there was a significant 
reduction in the rate of ferritin three months after study 
begin (P=0.046) but six months after intervention it 
wasnot significant compared with baseline. 
The average values of ferritin amount three and six 
months after intervention was decreased in male but in 
female this rate was increased. There wasn’t significant 
relation between two sexes and changing of the ferritin 
level. The average subcutaneous Deferoxamine reduction 
rate was 32 and 49 units in male and female three months 
after intervention but not statistically significant. Also, 
the average subcutaneous Deferoxamine reduction rate 
was 42 and 66 units in males and females six months 
after intervention but not statistically significant. 
Results showed that in none of age groups there were 
significant differences between subcutaneous 
Deferoxamine and ferritin three and six months after 
study intervention compared with baseline (Table 1). 
 
Table 1: Changes in ferritin and subcutaneous 
Deferoxamine amount three and six months after 
intervention by age groups. 
Differences 
Age 
group 
Mean 
value 
SD 
P-
value 
Difference between 
mean values of 
ferritin and baseline 
three months after 
intervention 
7-14 -523 270 
0.43 
14-21 -336 702 
21-28 -298 293 
Difference between 
mean values of 
subcutaneous 
Deferoxamine and 
baseline three 
months after 
intervention 
7-14 -12 27.4 
0.45 
14-21 -53 21.4 
21-28 -49 22.3 
Difference between 
mean values of 
subcutaneous 
Deferoxamine and 
baseline six months 
7-14 -27.6 814 
0.43 
14-21 -68.4 1817 
21-28 -60.5 2116 
14-21 -7.1 7.1 
21-28 -7.2 24.2 
DISCUSSION 
The efficacy of using higher doses of Deferoxamine 
(more than 10 mg per kg of body weight per hour) have 
been studied in various studies and researchers have 
concluded that higher doses of Deferoxamine, especially 
in patients with high serum ferritin, compared to the 
commonly used doses, are more effective in reducing 
complications and improving patients' quality of life.
15,16
 
Cardiac complications due to iron overload lead to 71% 
of mortality in major thalassemia patients and currently, 
Deferoxamine is the only used drug for iron removal in 
clinical centers.
14
 In our study patients received 
intravenous Deferoxamine (100 mg per one kg of body 
weight) with monthly blood transfusion by infusion 
during 8 hours and after follow-up period, patients have 
lower rate of ferritin compared with baseline. 
Intravenous administration of Deferoxamine has positive 
effect on high risk thalassemia major patients and patients 
with heartproblems.
13,17,18 
Some experts believe that the 
vitamin C has useful effect on increasing urinary 
excretion of iron by Deferoxamine.
18
 Also, in this study 
50 mg vit C for patients younger than 10 years and 100 
mg vit C for patients over 10 years old was given by 
orally before Deferoxamine infusion. 
According to results, three months after intervention there 
was a significant reduction in the rate of ferritin 
compared with baseline values (P=0.046) but this 
reduction was not statistically significant six months after 
intervention which can be due to decreasing arbitrary use 
of daily subcutaneous Deferoxamine by patients. Some 
studies reported that the intravenous application of 
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Deferoxamine can be effective in improving cardiac 
function of patients.
17-19 
In our study after intervention the 
usage of subcutaneous Deferoxamine in average was 
significantly decreased followed by reduction in the 
amount of medication side effects and health care costs.
20
 
Mashhadi et al showed that the concomitant use of 
Deferoxamine and Deferiprone was effective in reducing 
ferritin values but the symptoms such as dysplasia, 
nausea, joint pain and stiffness were seen in 13-18 % of 
the patients.
19
 
It is noted that none of the patients in our study suffered 
from acute complication of intravenous Deferoxamine 
and were not excluded due to complications caused by 
Deferoxamine in follow up period. It seems that the 
intravenous Deferoxamine Concominant with Blood 
Transfusion in thalassemia major patients will be 
considerable help to the improvement of iron loading. 
Davis et al in a study showed that administration of 24-
hour intravenous Deferoxaminewith appropriate dose via 
the catheter leads to improving serum ferritin condition 
and significantly reduces half the initial values.
13
 
Wali and et al showed that one year after using high-dose 
intravenous Deferoxamine (200-240 mg per kg per day) 
with subcutaneous infusion through three days (every 10 
hours), the serum ferritin and urinary excretion of iron (as 
a measure of iron overload) have decreased 
significantly.
15
 
According to the results of our study and those of other 
studies, intravenous Deferoxamine has positive effect on 
reducing serum ferritin amount (as the most important 
and accessible marker of iron overload in the body).
9-11
 
Calvaruso et al showed that the Deferiprone shows same 
effectiveness and survival rate versus Deferoxamine with 
controlled safety profile and found the possibility of 
using this drug in thalassemia patients which was similar 
to our study results.
21
 
Elalfy and et al in a study entitled “Efficacy and safety of 
a novel combination of two oral chelators Deferasirox/ 
Deferiprone over Deferoxamine/ Deferiprone in severely 
iron overloaded young beta thalassemia major patients” 
showed that both iron chelation combination regimens 
were equally effective in reducing iron overload and 
improving Quality Of Life. Deferoxamine/ Deferiprone 
combination proved superior in improving cardiac T2, 
treatment compliance, and patient’s satisfaction with no 
greater adverse events. The results of our study disagree 
with their results.
22
 
Xia et al in a meta-analysis showed that in comparing 
DFX with DFO, a significant difference was shown on 
SF level (P=0.003), and there was no difference between 
DFX and DFO in safety evaluation. The results of this 
study were similar to our results.
20
 
Limitation  
Because of ethical considerations we could not take 
healthy normal subjects as control group and so, the study 
had to be done as a quasi-experimental similar to before-
after study in one group. Due to differences in dosage, 
duration, time of consuming and diet recommendations, it 
seems that more research with a larger sample size and 
longer follow-up period is needed in this area to achieve 
an exact evaluation of this regime. 
CONCLUSION 
Intravenous Deferoxamine concomitant use with monthly 
blood transfusion in thalassemia major patients leads to 
decreasing of serum ferritin, avoiding unpleasant 
subcutaneous Deferoxamine administration without any 
increasing in the complications. Therefore, by applied 
this method with adjusting dosage of Deferoxamine 
according to the decreasing rate of ferritin, we could 
effectively reduce health care costs, complications of 
treatment and finally improve patients care. Also, this 
method can be used in treatment of Splenectomized 
patients. 
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